Immunotherapy combo shows promise for chinese cancer patients
NCT ID NCT03195478
First seen Jun 26, 2026 · Last updated Jun 26, 2026 · Updated 1 time
Summary
This study tested a combination of two immunotherapy drugs, nivolumab and ipilimumab, in 37 Chinese patients with advanced solid tumors that had not responded to prior treatment. The main goals were to check safety and see if the drugs could shrink tumors. The trial is now complete, and results will help determine if this combination is a viable option for this population.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
nivolumab and ipilimumab (immunotherapy drugs)
What this could lead to
If it works, this could offer a new treatment option for Chinese patients with advanced solid tumors that have not responded to other therapies.
What could go wrong
This is an early-phase trial with only 37 participants, so results may not apply to everyone. The combination can cause serious immune-related side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Local Institution
Guangzhou, Guangdong, 510080, China
-
Local Institution
Zhengzhou, Henan, 450052, China
-
Local Institution - 0001
Beijing, Beijing Municipality, 100142, China
-
Local Institution - 0004
Tianjin, Tianjin Municipality, 300222, China
-
Local Institution - 0011
Harbin, Heilongjiang, 155040, China
-
Local Institution - 0012
Guangzhou, Guangdong, 510655, China
-
Local Institution - 0013
Hangzhou, Zhejiang, 310009, China
-
Local Institution - 0015
Beijing, Beijing Municipality, 100021, China
-
Local Institution - 0016
Shanghai, Shanghai Municipality, 200025, China
-
Local Institution - 0018
Chengdu, Sichuan, 610041, China
-
Local Institution - 0020
Xi'an, Shan1xi, 710061, China
-
Local Institution - 0021
Wuhan, Hubei, 430030, China